# EDGAR Filing Document

**Accession Number:** 0002030763
**File Stem:** 0000000000-25-009795
**Filing Date:** 2025-9
**Character Count:** 4255
**Document Hash:** 153dd2e5a17d81db9ec126896dba5dbc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-009795.hdr.sgml**: 20260304

**ACCESSION NUMBER**: 0000000000-25-009795

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250910

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Wellgistics Health, Inc.
- **CENTRAL INDEX KEY:** 0002030763
- **STANDARD INDUSTRIAL CLASSIFICATION:** WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 933264234
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 377-07892

**BUSINESS ADDRESS:**
- **STREET 1:** 3000 BAYPORT DRIVE SUITE 950
- **CITY:** TAMPA
- **STATE:** FL
- **ZIP:** 33607
- **BUSINESS PHONE:** 1-843-302-1785

**MAIL ADDRESS:**
- **STREET 1:** 3000 BAYPORT DRIVE SUITE 950
- **CITY:** TAMPA
- **STATE:** FL
- **ZIP:** 33607

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Danam Health, Inc
- **DATE OF NAME CHANGE:** 20240717
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001641172-25-004615

## Text-Extract

```

                                                            September 10, 2025

Brian Norton
Chief Executive Officer
Wellgistics Health, Inc.
3000 Bayport Drive, Suite 950
Tampa, FL 33607

       Re: Wellgistics Health, Inc.
           Amendment No. 1 to Registration Statement on Form S-1
           Filed August 29, 2025
           File No. 333-288932
Dear Brian Norton:

     We have reviewed your amended registration statement and have the
following
comment(s).

        Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe a comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments. Unless
we note
otherwise, any references to prior comments are to comments in our August 8,
2025 letter.

Amendment No. 1 to Registration Statement on Form S-1
Prospectus Summary
Recent Developments
XRP Treasury Strategy, page 2

1.     We note your disclosure that you plan on launching a XRP Treasury
Strategy, targeted
       for the third quarter of 2025. Please expand your disclosure to describe
whether you
       will be relying on third-parties to hold XRP, and whether future XRP
payments
       received in connection with your business operations will be considered
part of your
       "XRP Treasury Strategy." If not, please revise to state how you plan to
treat the
       cryptocurrency received in connection with business operations
differently, including,
       if applicable, how you plan on using digital assets to support your
pharmacy
 September 10, 2025
Page 2

       customers. Lastly, please make corresponding changes to your Risk
Factors, as
       appropriate.
2.     Please update your disclosure here to provide a more comprehensive
description of
       your XRP Treasury Strategy, including material provisions of the
policies and
       arrangements governing your exchange of cash for XRP and/or other
digital assets.
       Disclose whether you have policies governing the percentage of your
treasury
       holdings that will be held as cryptocurrencies. To the extent that you
have already
       purchased XRP, please revise to disclose your purchases to date.
3.     Please identify the third-party advisors, if any, involved in the
execution of your
       XRP Treasury Strategy, how you determined to retain or engage with them,
and
       describe their various roles and material terms of your arrangements
with them.
      Please contact Nicholas Nalbantian at 202-551-7470 or Dietrich King at
202-551-
8071 with any questions.

                                                             Sincerely,

                                                             Division of
Corporation Finance
                                                             Office of Trade &
Services
cc:   Kate Bechen

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._